A. Laplanche

6.1k total citations · 2 hit papers
82 papers, 4.6k citations indexed

About

A. Laplanche is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, A. Laplanche has authored 82 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 20 papers in Surgery. Recurrent topics in A. Laplanche's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (9 papers) and Neuroendocrine Tumor Research Advances (8 papers). A. Laplanche is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (9 papers) and Neuroendocrine Tumor Research Advances (8 papers). A. Laplanche collaborates with scholars based in France, Italy and Switzerland. A. Laplanche's co-authors include R. Arriagada, Thierry Le Chevalier, Michèle Tarayre, Élisabeth Quoix, Jean‐Yves Douillard, María P. Martín, Brian Weinerman, Rut Isacson, J. Fryer and J Pater and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

A. Laplanche

80 papers receiving 4.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.

1998 789 citations A. Laplanche et al. Journal of Clinical Oncology profile →
Radiotherapy Alone Versus Combined Chemotherapy and Radiotherapy in Nonresectable Non-Small-Cell Lung Cancer: First Analysis of a Randomized Trial in 353 Patients

1991 623 citations Thierry Le Chevalier, R. Arriagada et al. JNCI Journal of the National Cancer Institute profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
A. Laplanche	2.7k	1.9k	1.1k	689	531	82	4.6k
Bernhard C. Pestalozzi	2.9k 1.1×	1.7k 0.9×	1.1k 1.0×	555 0.8×	992 1.9×	107	4.6k
Dido Franceschi	1.8k 0.7×	1.9k 1.0×	1.8k 1.7×	508 0.7×	460 0.9×	140	4.5k
Gabriela Kornek	3.7k 1.4×	1.7k 0.9×	1.6k 1.4×	672 1.0×	834 1.6×	161	6.3k
A. Aupérin	1.2k 0.5×	1.3k 0.7×	839 0.8×	456 0.7×	322 0.6×	77	3.2k
M K Palmer	2.0k 0.7×	1.0k 0.5×	737 0.7×	273 0.4×	567 1.1×	51	3.9k
Kai Oliver Jensen	1.4k 0.5×	1.1k 0.5×	1.5k 1.4×	879 1.3×	715 1.3×	52	4.0k
Severin Gloor	1.4k 0.5×	1.0k 0.5×	1.4k 1.3×	889 1.3×	718 1.4×	15	3.7k
Omar Abdel‐Rahman	2.9k 1.1×	1.7k 0.9×	974 0.9×	527 0.8×	791 1.5×	331	5.1k
G. Ganem	3.3k 1.2×	1.1k 0.6×	842 0.8×	993 1.4×	438 0.8×	68	4.5k
Per Pfeiffer	3.9k 1.4×	1.8k 0.9×	1.9k 1.7×	639 0.9×	1.2k 2.3×	302	6.3k

Countries citing papers authored by A. Laplanche

Since Specialization

Citations

This map shows the geographic impact of A. Laplanche's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Laplanche with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Laplanche more than expected).

Fields of papers citing papers by A. Laplanche

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Laplanche. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Laplanche. The network helps show where A. Laplanche may publish in the future.

Co-authorship network of co-authors of A. Laplanche

This figure shows the co-authorship network connecting the top 25 collaborators of A. Laplanche. A scholar is included among the top collaborators of A. Laplanche based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Laplanche. A. Laplanche is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fizazi, Karim, Gwénaëlle Gravis, L. Geoffrois, et al.. (2014). Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial. Annals of Oncology. 25(5). 987–991. 40 indexed citations

Gross‐Goupil, Marine, A. Fourcade, Emmanuel Blot, et al.. (2012). Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial. European Journal of Cancer. 48(5). 721–727. 33 indexed citations

Farace, F, Christophe Massard, Nadège Vimond, et al.. (2011). A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. British Journal of Cancer. 105(6). 847–853. 325 indexed citations

Péchoux, C. Le, A. Laplanche, Corinne Faivre‐Finn, et al.. (2010). Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Annals of Oncology. 22(5). 1154–1163. 130 indexed citations

Massard, Christophe, A. Laplanche, Elodie Tournay, et al.. (2010). Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Annals of Oncology. 21(9). 1864–1869. 30 indexed citations

Massard, Christophe, J J Voigt, A. Laplanche, et al.. (2007). Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?. British Journal of Cancer. 97(7). 857–861. 35 indexed citations

Motamed, Cyrus, et al.. (2006). An Analysis of Postoperative Epidural Analgesia Failure by Computed Tomography Epidurography. Anesthesia & Analgesia. 103(4). 1026–1032. 70 indexed citations

Théodore, Christine, François Bidault, Karim Fizazi, et al.. (2006). A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Annals of Oncology. 17(6). 990–994. 33 indexed citations

Mamelle, G., Stéphane Temam, Odile Casiraghi, et al.. (2006). Place et perspectives du ganglion sentinelle dans les tumeurs des voies aérodigestives supérieures. Cancer/Radiothérapie. 10(6-7). 349–353. 1 indexed citations

10.

Fléchon, Aude, et al.. (2005). The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. British Journal of Cancer. 93(8). 909–914. 42 indexed citations

11.

Bonvalot, Sylvie, A. Laplanche, F. Lejeune, et al.. (2005). Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-α be better?. Annals of Oncology. 16(7). 1061–1068. 90 indexed citations

12.

Théodore, C, Marie‐José Terrier‐Lacombe, A. Laplanche, et al.. (2004). Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy. British Journal of Cancer. 90(1). 55–59. 43 indexed citations

13.

Leboulleux, Sophie, J.P. Travagli, Bernard Caillou, et al.. (2001). Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome. Cancer. 94(1). 44–50. 67 indexed citations

14.

Laplanche, A., T. Delozier, J Berlié, et al.. (2000). Polyadenylic–Polyuridylic Acid Plus Locoregional Radiotherapy Versus Chemotherapy with CMF in Operable Breast Cancer: a 14 Year Follow-up Analysis of a Randomized Trial of the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Breast Cancer Research and Treatment. 64(2). 189–191. 35 indexed citations

15.

Sigal, R., A M Zagdanski, G Schwaab, et al.. (1996). CT and MR imaging of squamous cell carcinoma of the tongue and floor of the mouth.. Radiographics. 16(4). 787–810. 59 indexed citations

16.

Bolla, M., et al.. (1994). Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. European Journal of Cancer. 30(6). 767–772. 83 indexed citations

17.

Rougier, Philippe, A. Laplanche, M Huguier, et al.. (1992). Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial.. Journal of Clinical Oncology. 10(7). 1112–1118. 436 indexed citations

18.

Laplanche, A. & E Benhamou. (1991). [Estimation of cancer incidence in France].. PubMed. 78(5). 405–14. 8 indexed citations

19.

Chevalier, Thierry Le, R. Arriagada, Élisabeth Quoix, et al.. (1991). Radiotherapy Alone Versus Combined Chemotherapy and Radiotherapy in Nonresectable Non-Small-Cell Lung Cancer: First Analysis of a Randomized Trial in 353 Patients. JNCI Journal of the National Cancer Institute. 83(6). 417–423. 623 indexed citations breakdown →

20.

Carde, Patrice, et al.. (1989). Classical external indwelling central venous catheter versus totally implanted venous access systems for chemotherapy administration: a randomized trial in 100 patients with solid tumors. European Journal of Cancer and Clinical Oncology. 25(6). 939–944. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact